Non-Small Cell Lung Cancer (NSCLC) is a common type of lung cancer that often occurs in men and women. Approximately about 85% to 90% of lung cancers are Non-Small Cell Lung Cancer (NSCLC). According to the statistics, the global Non-Small Cell Lung Cancer (NSCLC) drug industry will rise from USD 4.3 billion to USD 6.9 billion in the time period of 2009 to 2019 with a CAGR growth of 4.84%.
Although NSCLCs are usually associated with activities such as cigarette smoke, adenocarcinomas is a type of disease that may be found in patients who have never smoked before. The NSCLC drugs market will expand and grow due to aspects such as cigarette smoking, secondary lifestyle, and several other agents that are released in the air as radon and asbestos.
The market forecasts that the NSCLC drug industry will continue its upward trend, resulting in an increasingly fragmented market through customized medicines until 2019. Such a high growth forecast is majorly attributed due to factors like rising population growth, strong pipeline landscape, and release of brand new first-in-class drugs with better efficacy and safety.
Whether you are worried about making sound decisions about the lung cancer treatment, developing lung cancer, or trying to maintain the health after treatment, ResearchMoz market research reports based on Non-Small Cell Lung Cancer (NSCLC) acts as your detailed guide of information. All our reports are created using data and information sourced from primary and secondary research and proprietary databases with the help of in-house research experts and analysts.